Date: 2014-03-19
Type of information: R&D agreement
Compound: pneumococcal conjugate vaccine
Company: Sanofi Pasteur (France) SK Chemical (South Korea)
Therapeutic area: Infectious diseases
Type agreement: R&D
manufacturing
production,
commercialisation
Action mechanism:
Disease: pneumococcal infections
Details: * On March 19, 2014, Sanofi Pasteur, the vaccines division of Sanofi, announced a long-term strategic cooperation with SK Chemical Co. to co-develop an innovative pneumococcal conjugate vaccine (PCV).
The collaboration agreement includes research & development, production, and commercialization of a preventative pneumococcal disease vaccine. As part of the agreement, Sanofi will make an up-front payment of $23 million to SK Chemical Co. Both companies will co-invest in the development of the PCV vaccine project and, if successful, SK Chemical would produce the innovative vaccine at its production facility located in An-dong--the southern part of Korea. The product, once registered, would be launched globally by Sanofi Pasteur with shared profits outside of Korea, where SK would commercialize it with exclusive rights.
Financial terms:
Latest news:
